Topics: Neuro Therapies
Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.
Although Nuvectra has entered a market dominated by industry giants (Boston Scientific, Medtronic, and Abbott), Nuvectra CEO Scott Drees is not fazed at the prospect of being the David among these Goliaths, particularly given his experience taking on Medtronic when he was with Advanced Neuromodulation Systems in 1996.
But how does Nuvectra plan to compete with the big players in this space? What are the company’s strategies for growth? How is Nuvectra positioning itself in the market place? To find out the answers to these questions and more, BioMedGPS interviewed Drees at the North American Neuromodulation Society (NANS) 2017 Annual Meeting in Las Vegas in January.
Interview Questions By Timecode:
0:00 It’s been almost a year since Nuvectra spun-off from Greatbatch. Can you discuss the company’s growth to date, and what your priorities have been the first year in getting established in the market?
2:28 The spinal cord stimulation market is rapidly evolving, with new technologies and waveforms. How are you positioning Nuvectra in the market place?
5:08 Sounds like you already are expanding indications, and are looking at some other neuromodulation segments and novel technologies. Anything else in the pipeline that you can discuss?
6:25 What’s next for the company?